IFI-M · ASB Tri-Axis Balanced Series

Specimen SS-F-M3-02607 // MULTI-AXIS · IFI-M

ASB Tri-Axis Balanced Series II-BL

Vitis vinifera

Grape

Tier IIASB Tri-Axis Balanced Series

Target Trait

1.38×

fold-change

Astringency+Sweet+Bitter-Attenuation balanced tri-axis fold-change

Technical Specifications

SKU

SS-F-M3-02607

Genomic Edits

7

GC Content

46%

Construct Length

4,567 bp

Promoter System

CaMV 35S / Ubiquitin

Expression System

Biolistic transformation

Host Strain

Particle Gun

Receptor Target

Polyphenol-astringency axis + TAS1R2/TAS1R3 + TAS2R38 (suppression)

IFI Score

138

Pathway Edits

  • Polyphenol-astringency axis pathway primary gene cluster for astringency (IFI-A) tri-axis component
  • TAS1R2/TAS1R3 pathway primary gene cluster for sweet (IFI-S) tri-axis component
  • TAS2R38 (suppression) pathway primary gene cluster for bitter-attenuation (IFI-B) tri-axis component
  • Tri-axis metabolic flux partitioning hub for concurrent ASB pathway operation
  • Cross-pathway regulatory circuit for balanced ASB triple-axis expression
  • Cofactor regeneration system (NADPH, ATP, acetyl-CoA) supporting triple-axis concurrent production

Key Interventions

Triple-axis receptor co-activation: Polyphenol-astringency axis, TAS1R2/TAS1R3, and TAS2R38 (suppression) pathways simultaneously engineeredBalanced tri-axis expression strategy (ASB) with cross-pathway flux managementBiolistic co-bombardment of multi-axis transgene cassettes for high-copy integration events

IFI Subscale Profile

IFI Profile

IFI-S
—
IFI-U
—
IFI-B
—
IFI-K
—
IFI-C
—
IFI-P
—
IFI-A
—
IFI-F
—

Use Case

Tier II ASB triple-axis construct for advanced multi-modal sensory architecture combining astringency, sweet, and bitter-attenuation axes. Suitable for ultra-premium ingredient formulation requiring certification across three simultaneous IFI receptor pathways.

License

$699 · Tier II License

Includes full construct sequence, CRISPR guide designs, pathway edit specifications, flux balance analysis, and IFI validation data.

Already purchased?